CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) valuation

Bring your own price

Enter a share price and a discount rate — every multiple, the earning-power value and the reverse-DCF below recompute on the spot from CLOVER HEALTH INVESTMENTS, CORP. /DE's latest SEC EDGAR filings. Change either input and the whole page follows.

Share price (USD)

Discount rate (% per year)

Enter a share price to run the model.

The prefilled 8.9% is a plain CAPM cost of equity at β = 1: the 10-year Treasury yield (4.46%, 2026-06-18, U.S. Treasury 10-yr) plus the U.S. equity risk premium (4.46%, Damodaran 2026-01-01). Build a firmer per-company rate with the cost-of-equity and WACC calculators, then paste it here.

Share price — · awaiting your input

Market Capitalization

Equity value at your price

—

Price-to-Earnings

P/E · Trailing Diluted

—

Earnings Yield

EPS ÷ Price · Trailing

—

Price-to-Free-Cash-Flow

P/FCF · Trailing

—

Free-Cash-Flow Yield

FCF Yield · Trailing

—

Price-to-Sales

P/S · Trailing

—

Price-to-Book

P/B · Latest filing

—

Fundamentals from the filings

Every model input below comes straight from CLOVER HEALTH INVESTMENTS, CORP. /DE's SEC EDGAR XBRL filings — these are the denominators and bridge inputs the calculator pairs with your price and rate.

Trailing twelve months · TTM as of 2026-03-31 (Q1 FY2026)

Revenue: $2.21B
EBIT (GAAP): -$56.9M
EBIT margin: -2.6%
Operating cash flow: $57.3M
CapEx: $2.7M
D&A: $1.7M
Free cash flow: $54.5M
Stock-based comp: $89.5M
YoY revenue growth: 48.7%

Balance sheet · 10-Q · period ending 2026-03-31

Cash & equivalents: $173.3M
Total debt: —
Stockholders' equity: $339.4M
Excess cash: $173.3M

Share count

Diluted shares (TSM-scaled): 532.5M

Method: weighted-average diluted shares (no point-in-time count tagged). See the diluted-shares methodology for why this count denominates EPV/share and the reverse-DCF equity bridge.

Earning-Power-Value, reverse-DCF, and EV/EBITDA are hidden for this insurer. EPV and the reverse-DCF both anchor on an EBIT margin, but a insurer's "margin" is interest-spread × leverage with non-EBIT investment results mixed in; EV/EBITDA omits deposits and borrowings — the actual funding — so the multiple isn't interpretable. The trailing multiples above (P/E, P/S, P/B, P/FCF) still render, but the right lens here is price-to-tangible-book-value and ROE vs cost of equity — applied manually, outside this page.